Pazopanib: The newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma

Drugs

Volumn 71, Issue 4, 2011, Pages 443-454

  Keisner, Sidney V ^a,b   Shah, Sachin R ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Pazopanib; Renal cell carcinoma; Research and development

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; LAPATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPIGMENTATION; HYPOTHYROIDISM; IC 50; KIDNEY CARCINOMA; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; STEADY STATE; TAKOTSUBO CARDIOMYOPATHY; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANIMALS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79952543555     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11588960-000000000-00000     Document Type: Review

References (46)

1. Society AC. Cancer facts and figures 2010. Atlanta (GA): American Cancer Society, 2010.
2. DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2008.
3. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009 Nov; 76 (9): 939-45.
4. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010 Mar; 13 (1): 1-14.
5. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009 Jul 1; 27 (19): 3225-34.
6. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4- [(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2-m ethyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008 Aug 14; 51 (15): 4632-40.
7. GlaxoSmithKline. Votrient (pazopanib) tablets: full pre- scribing information. Research Triangle Park (NC): GlaxoSmithKline, 2010.
8. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pa- zopanib in patients with advanced cancer. Clin Cancer Res 2009 Jun 15; 15 (12): 4220-7.
9. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic- pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007 Jul; 6 (7): 2012-21. (Pubitemid 47052491)
10. Bayer HealthCare Pharmaceuticals Inc. Nexavar® (sor- afenib) tablets: full prescribing information. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc., 2009.
11. Pfizer Labs. Sutent® (sunitinib) capsules: full prescribing information. New York: Pfizer Labs, 2010.
12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: kidney cancer, V.2.2010 [online]. Available from URL: http://www.nccn.org/professionals/ physician-gls/-PDF/kidney.pdf [Accessed 2010 Jun 21].
13. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010 Feb 20; 28 (6): 1061-8.
14. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 Aug 1; 27 (22): 3584-90.
15. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370 (9605): 2103-11. (Pubitemid 350296300)
16. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008 Nov 20; 26 (33): 5422-8.
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 May 31; 356 (22): 2271-81. (Pubitemid 46849157)
18. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009 Jul 10; 27 (20): 3312-8.
19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349 (5): 427-34. (Pubitemid 36910021)
20. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 Mar 1; 22 (5): 909-18. (Pubitemid 41103603)
21. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 Jun 7; 295 (21): 2516-24. (Pubitemid 43854967)
22. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of ever- olimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 Aug 9; 372 (9637): 449-56.
23. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010 Jan 20; 28 (3): 475-80.
24. Plimack ER, Jonasch E, Bekele BN, et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study [abstract no. 325]. ASCO 2010 Genitourinary Cancers Symposium; 2010 Mar 5-7; San Francisco (CA).
25. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of su- nitinib malate plus interferon-alpha for patients with me-tastatic renal cell carcinoma. Clin Genitourin Cancer 2009 Jan; 7 (1): 28-33.
26. Ryan CW, Goldman BH, Lara Jr PN, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007 Aug 1; 25 (22): 3296-301. (Pubitemid 47325615)
27. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 Mar 20; 27 (9): 1432-9.
28. Sosman J. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008; 26 Suppl.: 5011.
29. Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009 Sep 20; 27 (27): 4469-74.
30. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosup- pression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009 Nov 17; 101 (10): 1717-23.
31. Routhouska S, Gilliam AC, Mirmirani P. Hair depig- mentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006 Nov; 142 (11): 1477-9. (Pubitemid 44790642)
32. Sideras K, Menefee ME, Burton JK, et al. Effect of pazo- panib on hair and skin hypopigmentation: a series of three patients [abstract]. J Clin Oncol 2010; 28 Suppl.: e13602.
33. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilir- ubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010 Apr 27; 102 (9): 1371-7.
34. Xu C, Reck BH, Goodman VL, et al. Association of the hemochromatosis (HFE) gene with pazopanib-induced transaminase elevations in renal cell carcinoma [abstract]. J Clin Oncol 2010; 28 (7 Suppl.): 3019.
35. White AJ, LaGerche A, Toner GC, et al. Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. Int J Cardiol 2009 Jan 24; 131 (3): e92-4.
36. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010 May 1; 28 (13): 2137-43.
37. Shibata S, Longmate J, Chung VM, et al. A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD) [abstract]. J Clin Oncol 2010; 28 (7 Suppl.): 2571.
38. Miller AA, Murry DJ, Owzar K, et al. Phase I and phar- macokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009 Apr 10; 27 (11): 1800-5.
39. Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2010; 28 (7 Suppl.): 3048.
40. Correia MA. Katzung BG. Basic & clinical pharmacology, 11e [online]. Available from URL: http://www.accessmedicine. com/content.aspx?aID=4515730 [Accessed 2009 Nov 2].
41. Chapter 1: clinical pharmacokinetic and pharmacodynamic concepts. In: Bauer LA. Applied clinical pharmacokinetics. 2nd ed. [online]. Available from URL: http://www.accessphar macy.com/content.aspx?aID=3517000 [Accessed 2009 Nov 2]
42. Maruo Y, Iwai M, Mori A, et al. Polymorphism of UDP- glucuronosyltransferase and drug metabolism. Curr Drug Metab 2005 Apr; 6 (2): 91-9. (Pubitemid 40394338)
43. Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010 Feb; 10 (1): 1-11.
44. Tan AR, Jones SF, Dowlati A, et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034) [abstract]. J Clin Oncol 2008; 26S (May 20 Suppl.): 3552.
45. Dejonge M, Savage S, Verweij J, et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazo-panib (P) and lapatinib (L) administered concurrently [abstract]. J Clin Oncol 2006; 24 (18 Jun 20 Suppl.): 3088.
46. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib+lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract]. J Clin Oncol 2008; 26S (May 20 Suppl.): 1016